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Abstract
Background: Patient immune status is thought to affect the efficacy of anti-malarial chemotherapy. This is a
subject of some importance, since evidence of immunity-related interactions may influence our use of
chemotherapy in populations with drug resistance, as well as assessment of the value of suboptimal vaccines. The
study aim was to investigate relationship between antibodies and anti-malarial drug treatment outcomes.
Methods: Some 248 children aged 0.5 and 15 years were recruited prior to the high malaria transmission season.
Venous blood (5 ml) was obtained from each child to measure antibody levels to selected malaria antigens, using
ELISA. Blood smears were also performed to assess drug efficacy and malaria infection prevalence. Children were
actively followed up to record clinical malaria cases.
Results: IgG levels to MSP3 were always higher in the successfully treated group than in the group with treatment
failure. The same observation was made for GLURP but the reverse observation was noticed for MSP1-19.
Cytophilic and non-cytophilic antibodies were significantly associated with protection against all three antigens,
except for IgG4 to MSP1-19 and GLURP.
Conclusion: Acquired anti-malarial antibodies may play an important role in the efficacy of anti-malarial drugs in
younger children more susceptible to the disease.
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Background
In areas of endemic parasite transmission, protective
immunity to Plasmodium falciparum malaria is acquired
over several years, in response to numerous disease epi-
sodes.. In vitro studies have shown that antibodies against
some malaria vaccine candidates (GLURP, MSP3, and
MSP1-19) play a protective role against malaria[1,2]. In
addition, epidemiological studies have shown that immu-
nity acquired over several years is strongly related to a
drop in mortality and morbidity within populations living
in malaria-endemic areas[3]. Although anti-malarial
vaccines are being produced and tested, the control of
malaria relies heavily on chemotherapy[4,5]. Many of the
available anti-malarial drugs are effective, cheap, and easy
to distribute. However, in recent years, the increase in
drug resistance throughout malaria-endemic regions has
been cause for great concern, and has led to calls for the
development of new anti-malarial measures, which would
involve a larger variety of drug targets as well as a wider
array of vaccine strategies[6,7]. In this context, any strate-
gies that maximize the effectiveness of drugs or subopti-
mal vaccines may lead to significant progress. Among
the factors upon which the efficacy of anti-malarial che-
motherapy is thought to depend is the patient’s immune
status[8]. This is a subject of some importance because
evidence of interactions may influence our use of
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chemotherapy in areas with drug resistance, as well as
our assessment of the value of suboptimal vaccines. The
aim of this study was to investigate whether antibodies
can play any direct contributory role in complementing
anti-malarial drug therapeutic response, and, if so,
whether this was associated with P. falciparum malaria
treatment outcomes.
Methods
Study area and population
Children in this study were aged between 0.5 and 15
years with uncomplicated malaria and were recruited in
the village of Balonghin, in the Saponé health district,
situated 50 km south of Ouagadougou. The population
of Balonghin (approximately 1,600) belongs almost exclu-
sively to the Mossi ethnic group and lives by subsistence
farming. The climate is characteristic of the Sudanese
savannah, with a dry season from November to May (low
transmission season) and a rainy season from June to
October (high transmission season). Malaria transmission
is markedly seasonal, and most transmission occurs dur-
ing the rainy season. The main vectors are Anopheles
gambiae and Anopheles funestus. Plasmodium falci-
parum is the predominant malaria parasite, accounting
for more than 95% of infections in children under five
years of age [8]. From February to May, the number of
bites per person per night (Entomological Inoculation
Rate, EIR) due to An. gambiae s.l. is negligible. However,
the EIR increases from June to September, then decreases
again from September to November and remains low
until the next rainy season. The use of insecticide-treated
nets in this area is very low, estimated at 1.3%. In addi-
tion, the use of indoor residual spraying is non-existent
in the area and malaria control mainly relies on treat-
ment of clinical cases[8,9]. To avoid the confounding fac-
tor of sickle cell genetic trait, only children homozygous
for haemoglobin AA were recruited. The research was
given ethical clearance from the National Ethics Commit-
tee of Burkina Faso.
Study design and sample collection
The study design has already been described elsewhere
[8]. Briefly, during a cross-sectional survey and prior to
the malaria transmission season, each child was seen by a
physician. Children exhibiting fever (axillary temperature
37.5°C or higher) were treated presumptively with a stan-
dard chloroquine and antipyretic (paracetamol/acetami-
nophen) drug regimen according to the national drug
policy. Five ml of venous blood was withdrawn into an
EDTA tube from each target child and the plasma
obtained was aliquoted and stored at -20°C for later
assessment of antibodies. Thick and thin blood smears
were performed by finger-prick for malaria diagnosis.
Afterwards, the children were enrolled for a longitudinal
follow-up study through biweekly home visits to assess
the efficacy of the two drugs, chloroquine and sulphadox-
ine/pyrimethamine, from early July to October. This
study is a sub-cohort of a study which study flow is
described elsewhere [8]. Drug allocation was performed
randomly using epi-info software. Malaria episode was
defined as fever (axillary temperature more or equal to
37.5°C) plus 5,000 P. falciparum asexual parasites/μl. The
WHO 2003 guidelines were used for assessment of drug
efficacy[10].
Malaria diagnosis
Thick and thin blood films were air-dried, thin blood
films were fixed with methanol, and both were stained
with 3% Giemsa. Parasite count was performed using
microscopy, by experienced technicians. One hundred
high power fields were examined and the number of
malaria parasites of each species and stage were recorded.
The parasite count was expressed as number of asexual
parasites per microliter of blood and was calculated
assuming a fixed white cell count of 8,000/μl. A slide was
declared negative if no parasites were found after 100
high-power field examinations.
Immunological assessment by ELISA
Antibody assays were performed in a blinded fashion by
personnel without knowledge of the microscopic and
clinical results of the patients. Levels of specific antibo-
dies (IgG, IgM, and IgG subclasses) were measured by
ELISA, using the MSP3 long synthetic peptide (MSP3),
recombinant GLURP from Escherichia coli, and recombi-
nant MSP1-19 from Baculovirus. The ELISA was done
according to the Afro Immuno Assay standard operating
procedures (SOP number AIA-007-03; AIA-001-03;
AIA-013-03), which have been described elsewhere[11].
In brief, microtiter plates (NUNC - Maxisorp F 96
439454) were coated with long synthetic peptides LR55
MSP3 (1 μg/ml), recombinant GLURP27-500 (0.5 μg/ml)
and recombinant MSP1-19 (1 μg/ml), incubated over-
night at 4°C, and blocked with 3% dry non-fat milk pow-
der in PBS-Tween 20 for one hour. Plasma samples,
diluted 1: 200 (IgG and IgM) or 1: 25 (IgG subclasses),
were added in duplicate and incubated at room tempera-
ture for two hours. Plates were washed four times
between steps. Plates were developed with either peroxi-
dase-conjugated goat anti-human IgG or peroxidase-
conjugated goat anti-human IgM (secondary antibody)
(Caltag - H10007, H 15007). For IgG subclasses, the sec-
ondary antibody was a mouse anti-human monoclonal
IgG subclass (Sigma I-9513, clone HP-6002 for IgG1 and
IgG2; Sky Bio, M08011, clone ZG4 for IgG3 and Sky Bio,
M11014, clone RJ4 for IgG4), and results were visualized
using peroxidase-conjugated goat anti-mouse IgG (Caltag
M3007). Bound secondary antibody for IgG and IgM and
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tertiary antibody for IgG subclasses were quantified by
colour, using ready-to-use TMB (3, 3’, 5, 5’-Tetramethyl-
benzidine) substrate. Optical density (OD) was read at
450 nm with a reference at 620 nm in a plate reader
(Multiskan Ascent, Finland), and the OD values of the
test sample were converted into arbitrary units (AU) by
means of a standard curve on each plate. The positive
controls were from malaria-positive Liberian plasma
samples and the negative controls were from Danish
plasma samples from Statens Serum Institute (Copenha-
gen, Denmark).
Data analysis
Data entry of case report forms for surveillance of
malaria episodes was performed using EPI info version
6.0. Data generated from assays in the form of ELISA OD
values were converted into Microsoft Excel worksheets
using the Auditable Data Analysis and Management
System for ELISA (ADAMSEL). Datasets were then
transferred to Stata version 8.0 for analysis [12]. Continu-
ous variables were log transformed. Age was coded into
categories: 0.5-3, 4-5, 6-10, and > 10 years. Levels of anti-
bodies were compared between age and drug efficacy
groups using a Student’s t-test. Linear regression was
fitted to account for the effect of age and sex on the effi-
cacy of the drugs used. Arbitrary units for total IgG and
subclasses were log transformed and their geometric
means were compared between age categories using
ANOVA.
Results
Characteristics of the study cohort
The study population consisted of 248 children, aged 0.5
to 15 years, living in the village of Balonghin. The children
were selected on the basis of a general census of the village
population. They all had AA genotypes for haemoglobin.
Regarding gender, 55.2% were male and 44.8% were
female. The mean age was 4.07 years. The main malaria
species was P. falciparum, with a geometric mean of
11,777 (9,182.954-15,104.28) parasites/μL.
Drug efficacy in the treatment of uncomplicated
Plasmodium falciparum malaria in the different age
groups
The rate of drug failure (corrected with PCR) in the vil-
lage of Balonghin (a rural area) was very high for both
drugs used during the follow-up period (Figure 1). The
rate of early treatment failure (ETF) was 14% for CQ
and 11% for SP. The rate of late treatment failure (LTF)
was 78% for CQ and 51% for SP. The overall failure rate
for both drugs was 92% and 62% for CQ and SP with an
Adequate Clinical and Parasitological Response (ACPR)
of 8% and 38%, respectively (Figure 1). The failure of
both drugs was more pronounced in younger children
compared with older ones: 98.3% vs 47.3% for CQ and
69.2% vs 0% for SP for younger vs older children,
respectively.
Association of antibody levels and efficacy of each drug
in the treatment of uncomplicated Plasmodium falciparum
malaria
To investigate whether the treatment efficacy for each of
the drugs assessed was associated with a background of
immunity, antibody responses to the investigated anti-
gens (MSP3, MSP1-19, and GLURP) were compared
according to each drug’s efficacy. Children were assumed
to be “protected” if they were able to clear the parasites
during the follow-up period, and “unprotected” if they
failed to clear the parasites during this period. It appears
that in the CQ group, total IgG (3.55 [3.31-3.78] vs 3.18
[3.12-3.25]; P = 0.01), IgG1 (0.98 [0.53-1.44] vs 0.44
[0.37-0.52]; P = 0.01), and IgG2 (0.42 [0.23-0.61] vs 0.21
[0.18-0.25]; P = 0.001) against MSP3 were all strongly
associated with drug efficacy. The same trend was
observed for IgG (3.91 [3.43-4.39] vs 0.44 [0.37-0.52];
P = 0.01) and IgM (2.20 [1.41-2.99] vs 0.97 [0.86-1.08];
P = 0.01) against GLURP. For the SP group, with the
exception of IgG3 (1.35 [0.67-2.04] vs. 0.67 [0.37-0.97];
P = 0.03) against MSP3, none of the other antigens
showed any relationship between efficacy and antibody
levels (Table 1). When adjusted for age only IgM to
MSP1-19 and GLURP and IgG2 to MSP1-19 in the
chloroquine group have shown significant relationship
between drug efficacy and antibodies levels.
Relationship between age and level of total IgG, IgG
subclasses, and IgM responses to MSP3, MSP1-19, and
GLURP
The study population was categorized by age group to
see whether there was a correlation between antibody
levels and age. The antibody levels were compared
between age groups using a Student’s t-test. The general
profile of the geometric mean (95% confidence interval)
of the antibody levels was found to increase rapidly with
age (Table 2), with the following exceptions: IgM to
MSP3; IgG1, IgG4, and IgG to MSP1-19; and IgG4 to
GLURP. The antigens GLURP and MSP3 responded well,
with more than two-fold and three-fold higher antibody
levels in older children (> 10 years) than in younger (0.5-
3 years) ones, respectively. Cytophilic IgG antibodies
(IgG1 & IgG3) were by far more highly expressed than
non-cytophilic IgG antibodies (IgG2 & IgG4) (Table 2).
Discussion
The data show high rates of failure for both drugs. The
same trend was observed during a follow-up study of
the two mentioned drugs in 2003, in Pissy, a neighbour-
hood in the capital city Ouagadougou (urban area) with
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LTF levels of 69.5% for CQ and 14.6% for SP[13]. These
data, combined with others from several malaria ende-
mic countries, show the real state of resistance to these
drugs, which have been used for a long time as first and
second line drug treatments for uncomplicated malaria
in many malaria endemic countries throughout the
world[14,15]. This raises a major point about the emer-
gence of the need for a change in drug policy to a more
effective one, such as combination therapy, which is
recommended by the WHO guidelines in many malaria-
endemic areas[16]. Resistance to anti-malarial drugs is
proving to be a challenging problem for malaria control
in most parts of the world. Since the early 1960s, the
sensitivity of the parasites to chloroquine, the best and
most widely used drug for treating malaria, has been on
the decline[17]. In the present study, the higher rates of
drug failure for both CQ and SP are far above the levels
at which the WHO recommends a change in drug pol-
icy. In Burkina Faso in 2005, because of the high rates





























Figure 1 Chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) efficacy (%). ETF: early treatment failure, LTF: late treatment failure, ACPR:
Adequate, Clinical and Parasitological Response.
Table 1 Relationship between antibodies levels and drug efficacy in treatment of uncomplicated P.falciparum malaria










MSP3 IgG 3.55(3.31-3.78) 16 3.18 (3.12-3.25) 179 0.001 0.78 3.42(3.17-3.66) 20 3.26(3.09-3.43) 33 0.27 0.79
IgM 1.34(1.16-1.53) 16 1.32(1.19-1.45) 179 0.91 0.53 1.48(1.06-1.90) 20 1.40(1.06-1.73) 33 0.75 0.73
IgG1 0.98(0.53-1.44) 16 0.44(0.37-0.52) 179 0.001 0.22 0.58(0.23-0.94) 20 0.56(0.27-0.84) 33 0.89 0.25
IgG2 0.42(0.23-0.61) 16 0.21(0.18-0.25) 179 0.001 0.19 0.29(0.13-0.44) 20 0.18(0.13-0.23) 33 0.09 0.69
IgG3 1.31(0.64-1.99) 16 0.84(0.67-1.01) 179 0.12 0.48 1.35(0.67-2.04) 20 0.67(0.37-0.97) 33 0.03 0.35
IgG4 0.04(0.01-0.09) 16 0.01(0.008-0.01) 179 0.01 0.29 0.03(0.001-0.08) 20 0.01(0.006-0.02) 33 0.32 0.91
MSP1-19 IgG 3.25(2.85-3.65) 16 3.19(3.10-3.28) 179 0.69 0.72 3.11(2.92-3.31) 20 3.22(3.01-3.44) 33 0.47 0.46
IgM 1.12(0.85-1.39) 16 1.25(1.16-1.34) 179 0.41 0.01 1.53(1.20-1.85) 20 1.30(1.09-1.50) 33 0.19 0.77
IgG1 1.67(0.95-2.38) 16 1.38(1.23-1.53) 179 0.27 0.50 1.38(0.98-1.78) 20 1.20(0.87-1.52) 33 0.47 0.29
IgG2 0.28(0.16-0.40) 16 0.23(0.19-0.27) 179 0.43 0.02 0.22(0.14-0.31) 20 0.19(0.14-0.24) 33 0.48 0.73
IgG3 0.85(0.54-1.16) 16 0.62(0.54-0.70) 179 0.12 0.85 0.63(0.45-0.81) 20 0.47(0.34-0.60) 33 0.14 0.18
IgG4 0.03(0.002.0.07) 16 0.03(0.009-0.06) 179 0.95 0.61 0.005(-0.001-0.01) 20 0.04(0.003-0.07) 33 0.14 0.13
GLURP IgG 3.91(3.43-4.39) 16 3.48(3.38-3.58) 179 0.01 0.68 3.58(3.33-3.82) 20 3.47(3.24-3.70) 33 0.54 0.68
IgM 2.20(1.14-2.99) 16 0.97(0.86-1.08) 179 0.001 0.02 1.08(0.82-1.33) 20 0.87(0.68-1.05) 33 0.17 0.89
IgG1 1.39(0.96-1.81) 16 1.05(0.92-1.17) 179 0.13 0.77 1.10(0.77-1.43) 20 1.20(0.84-1.56) 33 0.69 0.36
IgG2 0.68(0.48-0.88) 16 0.46(0.38-0.54) 179 0.11 0.76 0.54(0.29-0.79) 20 0.50(0.29-0.72) 33 0.82 0.65
IgG3 0.77(0.59-0.94) 16 0.64(0.57-0.71) 179 0.32 0.34 0.72(0.50-0.94) 20 0.59(0.48-0.71) 33 0.24 0.63
IgG4 0.006(-0.003-0.16) 16 0.02(-0.002-0.05) 179 0.57 0.30 0.04(-0.03-0.12) 20 0.02(-0.002-0.05) 33 0.63 0.83
N: number of children, GM*: geometric mean of Ig; P: P value not adjusted for age and sex, P*: P value adjusted for age and sex.
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line treatments, respectively, the anti-malarial drug pol-
icy was changed to combination therapy, as recom-
mended [13]. These results showed that the level of
total IgG and IgM against the three antigens, with the
exceptions of IgM to MSP3 and IgG and IgM to MSP1-
19, was higher in the group of children whose malaria was
cured compared with those whose treatment failed,
despite similar anti-malarial treatment regimens. A similar
finding had already been observed in other malaria ende-
mic areas, in case-control studies[8,18,19], suggesting a
supportive role for humoral antibodies in the therapeutic
response to anti-malarial drugs. As previously reported
[8,18,19], in most cases antibody responses (IgG, IgM and
IgG subclasses) to the tested antigens increased with
increasing age, in the current paper when adjusted with
age as confounding factor, no significant relationship was
found between antibodies levels and drug’s efficacy except
for IgM to MSP1-19 and GLURP and IgG2 to MSP1-19 in
the chloroquine group. These results are consistent with
previous studies that have suggested a protective role for
IgM antibodies against malaria infection[20,21] and for
IgG2 associated with lower risk of infection. Nevertheless,
evidence that anti-malarial treatment responses in
immune patients were always better than those in non-
immune patients was first observed by Yorke and colla-
borators while investigating malaria therapy for general
paralysis in early 1942 [18]. The fact that antibodies play
an important role in the development of premunition has
been well demonstrated [22-24]. Data obtained in the cur-
rent study have shown that antibody responses, mainly to
MSP3 and GLURP antigens, which are predominantly
cytophilic isotypes, are associated with protection. Several
immuno-epidemiological studies performed in geographi-
cally separated areas of Africa have reached the same con-
clusion; that high levels of two major malaria vaccine
candidate antigens (GLURP and MSP3) stimulate produc-
tion of specific cytophilic antibodies that are significant
predictors of protection against clinical malaria[1,11,25].
This provides epidemiological support for the concept that
antibodies against GLURP and MSP3 can actively control
parasite multiplication in vivo through cooperation with
cells bearing Fc II receptors [26]. The proof of a protective
effect by these two antigens has lead today to a large-scale
implementation of a candidate vaccine (GMZ2), which is
comprised of a combination of the two molecules
(GLURP and MSP3), in children under five years old in
several malaria epidemiological settings in Africa. These
two distinct mechanisms of parasite clearance (host
immunity and drug pressure) may play complementary
roles, and may thereby achieve efficacy when one mechan-
ism alone may have been insufficient. This observation has
been confirmed in a case-control study in which partial
immunity of the patient was shown to play an important
role even in the sensitivity of resistant parasites [24].
Conclusion
In malaria endemic zones, it is of paramount importance
to give treatment as soon as the diagnosis is made. But it
is not yet clear, however, how early treatment could
modify the development of protection to further infec-
tions, and knowledge of how a primary infection with the
malaria parasite may influence the immune response to
Table 2 Relationship between age and level of total IgG, IgG subclasses, and IgM responses to MSP3, MSP1-19, and
GLURP














MSP3 [0.5-3] 79 2.96 (2.88-3.04) 0.18 (0.14-0.23) 0.23 (0.21-0.24) 0.29 (0.22-0.37) 0.05 (0.04-0.06) 1.16 (1.06-1.28)
] 3-5] 69 3.22 (3.13-3.31) 0.24 (0.19-0.31) 0.22 (0.19-0.26) 0.49 (0.38-0.64) 0.05 (0.04-0.06) 0.99 (0.88-1.18)
] 5-10] 84 3.35 (3.25-3.45) 0.41 (0.33-0.52) 0.28 (0.25-0.30) 0.71 (0.56-0.92) 0.06 (0.05-0.07) 1.21 (1.06-1.39)
> 10 21 3.51 (3.30-3.70) 0.69 (0.40-1.21) 0.35 (0.26-0.47) 1.05 (0.63-1.75) 0.14 (0.03-0.54) 1.39 (1.12-1.73)
P 0,01 0,01 0,01 0,01 0,002 0,10
MSP1-19 ] 0.5-3] 79 3.13 (0.99-3.28) 1.19 (0.97-1.45) 0.21 (0.18-0.23) 0.40 (0.33-0.48) 0.02 (0.01-0.03) 0.86 (0.77-0.96)
] 3-5] 69 3.07 (2.95-3.19) 0.97 (0.80-1.17 0.26 (0.24-0.29) 0.48 (0.40-0.57) 0.03 (0.02-0.05) 1.22 (1.11-1.35)
] 5-10] 84 3.21 (3.07-3.34) 1.02 (0.86-1.21) 0.30 (0.27-0.34) 0.64 (0.54-0.75) 0,03 (0,03-0,09) 1.41 (1.29-1.54)
> 10 21 3.09 (2.89-3.31) 1.33 (0.96-1.86) 0.35 (0.27-0.45) 0.52 (0.37-0.74) 0.03 (0.02-0.05) 0.98 (0.77-1.25)
P 0,072 0.01 0.001 0.001 0.09 0.01
GLURP ] 0.5-3] 79 3.13 (3.02-3.25) 0.62 (0.51-0.76) 0.29 (0.26-0.32) 0.44 (0.38-0.50) 0.03 (0.01-0.06) 0.54 (0.45-0.65)
] 3-5] 69 3.41 (3.28-3.55) 0.77 (0.63-0.94) 0.36 (0.32-0.41) 0.55 (0.48-0.63) 0.01 (0.01-0.02) 0.80 (0.72-0.88)
] 5-10] 84 3.68 (3.53-3.84) 0.84 (0.69-1.09) 0.51 (0.43-0.61) 0.60 (0.52-0.68) 0.05 (0.02-0.09) 0.95 (0.84-1.09)
> 10 21 3.89 (3.58-4.22) 1.35 (0.96-1.88) 0.64 (0.51-0.82) 0.88 (0.66-1.17) 0.05 (0.02-0.09) 2.00 (1.47-2.73)
P 0.01 0.01 0.01 0.01 0.056 0.01
N: number of children, GM*: geometric mean of Ig
Diarra et al. Malaria Journal 2012, 11:79
http://www.malariajournal.com/content/11/1/79
Page 5 of 6
later infections is scarce. Nevertheless, these results sug-
gest that a background humoral immune response could
be beneficial to children during anti-malarial chemother-
apy. This information needs to be taken into account not
only for drug treatment policy, but also for malaria
vaccine development.
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